Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
Condition(s):Diffuse Large B Cell LymphomaLast Updated:September 21, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Diffuse Large B Cell LymphomaLast Updated:September 21, 2023Active, not recruiting
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:December 20, 2023Active, not recruiting
Condition(s):Newly Diagnosed Diffuse Large B-Cell Lymphoma; Intermediate (Burkitt-Like) LymphomaLast Updated:December 10, 2013Withdrawn
Condition(s):Diffuse Large B-cell LymphomaLast Updated:September 26, 2019Completed
Condition(s):Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Burkitt LymphomaLast Updated:November 20, 2017Terminated
Condition(s):Lymphoma, Large B-Cell, Diffuse; Lymphoma, FollicularLast Updated:August 28, 2020Completed
Condition(s):Burkitt Lymphoma; High-grade B-cell Lymphoma; T-cell/Histocyte-rich Large B-cell Lymphoma; Diffuse Large B-Cell Lymphoma (DLBCL); Germinal Center B-cell Type (GCB)Last Updated:December 13, 2023Completed
Condition(s):Diffuse Large B-Cell LymphomaLast Updated:September 28, 2022Terminated
Condition(s):Diffuse Large B Cell LymphomaLast Updated:August 23, 2023Recruiting
Condition(s):Diffuse Large B-cell Lymphoma (DLBCL)Last Updated:March 18, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.